Based on the results of research, IGF-1 related to insulin and a specific inhibitor of Smad3, and IL-17 antibodies related to inflammatory pathways, are expected to become targets for the prevention and treatment of acne-induced PSs, providing potential directions for new drug development. The gene discussed is SMAD3; the disease is acne.